Literature DB >> 12399766

Hair loss in women with hyperandrogenism: four cases responding to finasteride.

Kid Wan Shum1, Derek R Cullen, Andrew G Messenger.   

Abstract

Oral finasteride, a type II 5 alpha-reductase inhibitor, has been shown to increase hair growth and slow progression of thinning in men with androgenetic or male pattern balding (Hamiliton type) but has no affect on hair growth in postmenopausal women with female pattern hair loss (Ludwig type). We describe 4 cases of hair loss with characteristics of both male and female patterns in women with hyperandrogenism in which finasteride has improved or stabilized the alopecia. Improved hair growth was seen after 6 months, 1 year, 2 years, and 2.5 years, respectively. The finding that finasteride treatment improves pattern hair loss in women with hyperandrogenism but does not affect those postmenopausal women with female pattern hair loss without hyperandrogenism supports the concept that not all types of female hair loss have the same pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399766     DOI: 10.1067/mjd.2002.124608

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  17 in total

1.  Efficacy of Finasteride 1.25 mg on Female Pattern Hair Loss; Pilot Study.

Authors:  Won-Jeong Kim; Margaret Song; Hyun-Chang Ko; Byung-Soo Kim; Moon-Bum Kim
Journal:  Ann Dermatol       Date:  2012-07-25       Impact factor: 1.444

Review 2.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

3.  Polycystic ovary syndrome is linked with the fat mass obesity (FTO) gene variants rs17817449 and rs1421085 in western Saudi Arabia.

Authors:  Sherin Bakhashab; Asma A Batarfi; Najlaa Filimban; Osama S Bajouh; Ashraf Dallol; Mohammed H Alqahtani
Journal:  Bioinformation       Date:  2021-11-30

Review 4.  Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

Authors:  Jason M Hirshburg; Petra A Kelsey; Chelsea A Therrien; A Carlo Gavino; Jason S Reichenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

5.  [Androgenetic alopecia].

Authors:  R Hoffman
Journal:  Hautarzt       Date:  2004-01       Impact factor: 0.751

6.  Precision Medicine and the Practice of Trichiatry: Adapting the Concept.

Authors:  Ralph M Trüeb; Vicky M L Jolliffe; Antonia Fellas Régnier; Hudson Dutra Rezende; Sergio Vañó-Galván; Daisy Kopera; Demetrios Ioannides; Maria Fernanda Reis Gavazzoni Dias; Melanie Macpherson; Aida Gadzhigoroeva; Julya Ovcharenko; Won-Soo Lee; Sundaram Murugusundram; Sotaro Kurata; Mimi Chang; Chuchai Tanglertsampan
Journal:  Skin Appendage Disord       Date:  2019-08-20

Review 7.  Rooster feathering, androgenic alopecia, and hormone-dependent tumor growth: what is in common?

Authors:  Julie Ann Mayer; Cheng-Ming Chuong; Randall Widelitz
Journal:  Differentiation       Date:  2004-12       Impact factor: 3.533

8.  The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.

Authors:  Faris Azzouni; Alejandro Godoy; Yun Li; James Mohler
Journal:  Adv Urol       Date:  2011-12-25

Review 9.  Female pattern hair loss: current treatment concepts.

Authors:  Quan Q Dinh; Rodney Sinclair
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

Review 10.  Female pattern alopecia: current perspectives.

Authors:  Lauren L Levy; Jason J Emer
Journal:  Int J Womens Health       Date:  2013-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.